TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time to Hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time to Expiration
Endpoint domain: Mortality/survival
Primary endpoint: Change from Baseline in MATRICS Consensus Cognitive Battery scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in VO2Max (maximal oxygen consumption)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in 6-Minute Walk Test (6MWT) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Daily Functioning Assessments
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to first documented recurrence of symptomatic sustained AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients experiencing dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: baseline changes in pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protective rate of grade 4 neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Alprazolam bioavailability (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alprazolam bioavailability (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative cerebral desaturation incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline of PASI index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety Complication Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Food Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: composite of maternal complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of neonatal morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilator Associated Events (VAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of diabetic foot ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: EPA Area Under the Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: DHA Area Under the Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lipid core burden index (LCBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of Astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limb Fat changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Liver attenuation (Δ HU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EUS-FNB procurement yield of tissue core
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of height standard deviation score for chronological age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite of mortality and severe short term neonatal morbidities
Endpoint domain: Mortality/survival
Primary endpoint: RUC-4 Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient understanding of medication regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sustained virological response (undetectable HCV RNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of abnormal laboratory results
Endpoint domain: Adverse events/effects
Primary endpoint: Ductal closure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Work Behavior Inventory
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Total Brain Power Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total divided attention post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total set-shifting post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes from baseline in Mini-Mental State Examination (MMSE) scale scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes from baseline in Disability Assessment for Dementia (DAD) scale scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes from baseline in Neuropsychiatric Inventory (NPI) scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Freedom from Binary Restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Zoster development
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor size assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in hs-CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in oxidative stress status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in asthma severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of progression at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of Neovascular Area (NA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Vessel Caliber (VC), Measuring the Mean Diameter of the Corneal Vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Invasion Area (IA), Measuring the Fraction of the Total Corneal Area Invaded by the Vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Sleep quality assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daytime sleepiness measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of the Operating Room Nurses About Radiation Exposure
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attitude of the Operating Room Nurses About Radiation Exposure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: inflammatory lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cochlear microphonic amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysphagia evaluation: MBSimp
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft tissue edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voice evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stony Brook Scar Evaluation Scale (SBSES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Composite of Valve Thrombosis and Valve-related Thromboembolism
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of non-alcoholic fatty liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AUC0-last of Budesonide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-last of Formoterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy for disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worsening of respiratory symptoms (cough and/or dyspnea)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ability to provide support
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Motor function measured by GMFCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor function measured by GMFM-88
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Percentage of FEV1 Post Allergen Challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline in Foot and Ankle Disability Index (FADI) at 6 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline in Foot and Ankle Disability Index (FADI) at 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Coverage of the Clinical Target Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose to the Organs At Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the WOMAC Pain Subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrophysiological improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure measurement using ABPM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response rate of EGF ointment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rotational and anterior-posterior movement of tibia to femur
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Area under the blood concentration curves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Verification of lymph node status regarding tumour spread
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum Cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change in Yale Global Tic Severity Scale (YGTSS) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Serum Triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in Unified Parkinson's Disease Rating Scale (UPDRS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence and volume of MSU crystal deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: Maximum Observed Serum Concentration for Vedolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vedolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for Vedolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Substance use outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physical Activity Levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Extended Aberdeen Back Pain Scale (EABPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Percent Predicted Hemoglobin (Hb) and Altitude-Adjusted Diffusing Capacity of the Lung for Carbon Monoxide (DLco) at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Splenomegaly-Related Score (SRS) at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electroretinogram scotopic maximal b-wave amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient Pain Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Status of COVID-19 Patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Hemay005 in treating Behçet's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitisation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in child anxiety diagnostic status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in child anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 24 hours BGL > 8.3mmol/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Outpatient High Dose Methotrexate Courses Resulting in Inpatient Hospital Admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Quantification of the fluorescent signal of ICG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure of delayed abdominal fascial closure (non-prevented ventral hernia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intolerance of Uncertainty
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cumulative incidence of biopsy-proven CAN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Wrinkle Severity Rating Scale (SRS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC75-120 of Glucose Infusion Rate (GIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Inflammatory interleukins reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of subjects with anterior chamber cell grade of 0 and flare grade of 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Maximum-tolerated Dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Making at Least One Critical Error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital Anxiety and Depression Scale (HADS) change from baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Concentrations of Cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increased documentation of response to symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Palliative Performance Scale (PPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Illness understanding and advanced care planning
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of genetic causes of severe, early-onset obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cross-sectional area of the reconstructed ACL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: long to short axis ratio of the cross-sectional area of the reconstructed ACL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: long axis of the cross-sectional area of the reconstructed ACL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: short axis of the cross-sectional area of the reconstructed ACL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: dosage of seric markers (anti-SARS-CoV2 IgG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: genetic markers (genetic variants)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival index (GI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Self-reporting Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: hippocampal volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: RANKL concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OPG concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in daily step count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cfRNA markers associated with preeclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: cfRNA markers associated with fetal growth restrictions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Percentage of alive patients without detection of influenza A virus
Endpoint domain: Mortality/survival
Primary endpoint: Neuropsychiatric tests scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nightly agitation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MRI imaging of the lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Knowledge about Clinical Research
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Attitudes toward Clinical Research
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Self-Efficacy for Making Decisions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Readmission and emergency department visits due to HF decompensation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recurrent biliary obstruction (RBO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percent of Participants With Visit or Procedure With Provider
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Insulin Sensitivity measured by OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vaginal blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall Skin improvement assessed by a Visia Scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Overall Patient satisfaction of skin improvement assessed by the Global Aesthetic Improvement Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Patient satisfaction of skin improvement assessed by the Face-Q Aesthetic Satisfaction with Outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Patient satisfaction of skin improvement assessed by the Face-Q Aesthetic Satisfaction with Skin
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: overall survival at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Change in non-compliance rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain score of surgical wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: mean received radiation dose to salivary glands (Dmean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total uptake of PSMA in salivary glands (SUVtotal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative reduction of PSMA uptake after radiotherapy (ΔSUVtotal-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: assists
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evidence of ST Elevations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Range of Motion in Degrees of the Wrists
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amelioration of postpartum depression symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Influenza Illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Glucose AUC(0-4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Measurement of Acceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements of symptoms related to hypogonadism
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in testosterone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in gonadotropin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Systemic Lupus Erythematosus Disease Activity Index-2000 Glucocorticosteroid (SLEDAI-2KG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cement mantle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence of migraine-like attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in RLS severity rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes